Wild rabbits spotted with strange 'horn-like' growths sprouting from their heads
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
1 Stock Down 40% This Year to Buy and Hold
Key Points Novo Nordisk's shares have been trending downward due to clinical setbacks and underwhelming results. However, the company has some potential catalysts on the way that could jolt its stock price. Novo Nordisk looks attractive given its lineup and pipeline, especially at current levels. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market. However, the Denmark-based drugmaker has given up most of these gains over the past year; the stock is down by 40% since January alone. Despite its recent misfortunes, Novo Nordisk's shares could still deliver strong returns to patient investors. Here's why. The weight management opportunity Novo Nordisk primarily develops medicines for diabetes and, in recent years, weight management. Its stock has plunged over the past year because its financial results haven't been as impressive as the market had hoped. It also faced some clinical setbacks, while its biggest rival in its core markets, Eli Lilly, earned some important wins. However, there's more to the story. The market for anti-obesity medications could grow at an incredibly rapid rate. Some analysts estimate that it will be worth $150 billion by 2035, compared to $15 billion last year. Novo Nordisk still has one of the deepest pipelines in the industry. In fact, it's challenging to find a company other than Eli Lilly that has more promising products. Recently, Novo Nordisk expanded its pipeline through various licensing deals. Here's one more thing that recently broke its way: Eli Lilly's oral GLP-1 candidate, orforglipron, did not perform nearly as well as expected in a phase 3 study. This opens the door for Novo Nordisk to catch up to its longtime rival. The company's oral version of Wegovy is currently awaiting approval from regulators in the U.S. The oral version led to an average weight reduction of 13.6% in a phase 3 clinical trial, slightly higher than the 12.4% that orforglipron recently posted in its late-stage study. While it's always hard to compare across clinical trials, the data at the very least suggests that oral Wegovy is comparable to orforglipron -- but only the former drug is closing in on approval. Novo Nordisk also has yet another promising anti-obesity candidate in phase 3 studies, amycretin, which the Denmark-based pharmaceutical giant is testing in both subcutaneous and oral formulations. Why is the race to develop an oral weight loss option so important? Pills are easier and cheaper to manufacture, store, and transport. So, compared to injectable weight loss therapies, oral versions would allow drugmakers to produce them more cost-effectively and to expand the reach of weight loss therapies. On top of that, some patients are strongly averse to needles. Because the current leading weight management drugs are administered subcutaneously, an oral option would likely take a decent share of the market. Novo Nordisk is likely to be first to market. And the company could follow up that win with another oral product in amycretin. The price is right Let's go back to Novo Nordisk's recent and disappointing financial results. In the first half of the year, revenue rose by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit came in at 55.5 billion DKK ($8.7 billion). Perhaps that's not quite what the market expected to see, but these are still excellent results for a pharmaceutical giant -- most drugmakers of that size would be happy to grow their revenue at high-single-digit or low-double-digit rates. Meanwhile, the stock appears reasonably valued, trading at 13 times forward earnings, compared to the healthcare industry's average of 16.2. What's the verdict? Novo Nordisk looks attractive at current levels, given the company's strong pipeline in weight management and a lineup that continues to deliver consistent profits. Despite recent setbacks, the stock is well-positioned to deliver excellent results over the long term. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Stock Down 40% This Year to Buy and Hold was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
US suspends visas for Gazans after far-right influencer posts
The US government said Saturday it is suspending visitor visas for Gazans after a far-right influencer with the ear of President Donald Trump complained that wounded Palestinians had been allowed to seek medical treatment in the United States. The announcement came one day after a series of furious social media posts by Laura Loomer, who is known for promoting racist conspiracy theories and claiming that the 9/11 terrorist attacks were an inside job. "All visitor visas for individuals from Gaza are being stopped while we conduct a full and thorough review of the process and procedures used to issue a small number of temporary medical-humanitarian visas in recent days," the State Department, which is led by Marco Rubio, wrote on X. In a series of posts on X Friday, Loomer called on the State Department to stop giving visas to Palestinians from Gaza who she said were "pro-HAMAS... affiliated with the Muslim Brotherhood and funded by Qatar," without providing evidence. Loomer's target was the US-based charity HEAL Palestine, which said last week it had helped 11 critically wounded Gazan children -- as well as their caregivers and siblings -- arrive safely in the US for medical treatment. It was "the largest single medical evacuation of injured children from Gaza to the US," the charity said on its website. - 'Dangerous and inhumane' - "Truly unacceptable," Loomer wrote in another X post. "Someone needs to be fired at @StateDept when @marcorubio figures out who approved the visas." "Qatar transported these GAZANS into the US via @qatarairways," she said. Qatar is "literally flooding our country with jihadis," she added. Loomer said she had spoken to the staff of Republican Tom Cotton, who chairs the Senate intelligence committee, adding that they were "also looking into how these GAZANS got visas to come into the US." Republican Congressman Randy Fine explicitly commended Loomer after the visa change was announced, in a sign of her sway over some US policy. "Massive credit needs to be given to @LauraLoomer for uncovering this and making me and other officials aware. Well done, Laura," Fine wrote on X. The Palestine Children's Relief Fund, a US-based charity, called on the Trump administration to "reverse this dangerous and inhumane decision." Over the last 30 years the charity has evacuated thousands of Palestinian children to the US for medical care, it said a statement. "Medical evacuations are a lifeline for the children of Gaza who would otherwise face unimaginable suffering or death due to the collapse of medical infrastructure in Gaza." Though Loomer holds no official position, she wields significant power, and is reported to have successfully pushed for the dismissal of several senior US security officials she deemed disloyal to Trump. In July, Loomer took aim at a job offer made to a highly qualified Biden-era official for a prestigious position at the West Point military academy. The Pentagon rescinded the offer one day later. Trump also fired the head of the highly sensitive National Security Agency, Timothy Haugh, and his deputy Wendy Noble in April at the apparent urging of Loomer, after she met with the president at the White House. "No other content creator or journalist has gotten as many Biden holdovers fired from the Trump admin!" Loomer posted on X Saturday. nr/dl/sla Solve the daily Crossword
Fox News
4 hours ago
- Fox News
Nearly a million patients hit by DaVita dialysis ransomware attack
Healthcare institutions have become a favorite target for bad actors, largely because of how easy they make it for attackers. In June, researchers discovered a healthcare data breach that exposed the personal information of around 8 million patients. All of this information was publicly accessible online without any passwords or authentication protocols. The latest healthcare organization to fall victim to a breach is DaVita, which has put nearly a million people at risk. Headquartered in Denver, Colorado, DaVita provides dialysis treatment to about 200,000 patients across the U.S. and 13 other countries. Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide — free when you join my Kidney dialysis giant DaVita says nearly 916,000 people had personal and medical information exposed in an April ransomware attack (via Comparitech). The breach, which the company disclosed in state filings, compromised names, Social Security numbers, dates of birth, health insurance details, medical records, tax ID numbers, addresses and even images of checks made out to the company. DaVita says the incident disrupted internal operations and primarily affected its laboratories. In its latest notice to victims, the company says the cyberattack began March 24, 2025, and continued until April 12. It has not confirmed whether a ransom was paid. Ransomware gang Interlock claimed responsibility on April 25, posting screenshots of alleged stolen documents and saying it took 1.5TB of DaVita's data. The group lists the company on its public leak site, where it pressures victims by threatening to sell or release stolen files. DaVita is offering eligible breach victims free identity restoration services through Experian, with a Nov. 28 enrollment deadline. The company has not confirmed how attackers gained access to its network or the size of the ransom demand. CyberGuy reached out to DaVita for comment but did not receive a response before publication. Interlock, which first appeared in October 2024, has claimed responsibility for the DaVita attack and at least 23 other ransomware attacks, plus dozens more that remain unverified. Healthcare targets have included Texas Digestive Specialists, Kettering Health and Naper Grove Vision Care, all of which reported data breaches in 2025. The DaVita incident is the second-largest U.S. healthcare ransomware attack by number of records this year, behind Frederick Health's January breach. According to Comparitech, there have been 53 confirmed ransomware attacks on American healthcare providers in 2025 alone, compromising more than 3.2 million patient records. The DaVita data breach exposed sensitive patient information. If you are affected or just want to stay one step ahead, these actions can help minimize your risk. The DaVita data breach likely gives attackers access to your contact details, which they can misuse. Avoid clicking on unexpected emails or messages, even if they look legitimate. The best way to safeguard yourself from malicious links that install malware, potentially accessing your private information, is to have strong antivirus software installed on all your devices. This protection can also alert you to phishing emails and ransomware scams, keeping your personal information and digital assets safe. Get my picks for the best 2025 antivirus protection winners for your Windows, Mac, Android and iOS devices at Since your personal details were exposed in the DaVita breach, you're more vulnerable to targeted fraud. Consider using a personal data removal service to scrub your personal details from data broker websites that sell your information. While no service promises to remove all your data from the internet, having a removal service is great if you want to constantly monitor and automate the process of removing your information from hundreds of sites continuously over a longer period of time. Check out my top picks for data removal services and get a free scan to find out if your personal information is already out on the web by visiting Get a free scan to find out if your personal information is already out on the web: Reusing passwords increases your risk. A single leaked password can unlock multiple accounts. Use a password manager to generate and store secure passwords. Check out the best expert-reviewed password managers of 2025 at DaVita is offering free identity theft and credit monitoring services to those affected by the breach. But even if you weren't a victim of this specific breach, it's still smart to protect yourself. Identity theft protection services can alert you to suspicious activity, help you recover if your identity is stolen and often provide tools to freeze or lock your credit. That prevents fraudsters from opening new accounts in your name, and you can lift the freeze temporarily when needed. See my tips and best picks on how to protect yourself from identity theft at Adding a second layer of login protection, like a text message or app-based code via 2FA, can make it much harder for DaVita attackers to access your accounts, even if your password is exposed. Keep an eye out for strange charges or unfamiliar accounts. Set up alerts through your bank and review your credit report regularly to catch fraud early. The investigation into the DaVita breach is ongoing, and the company has not disclosed how the hackers got in. Nearly a million people now face the possibility of their personal information being used for malicious purposes. Ransomware attacks on hospitals and clinics can lock critical systems, delay care and push providers back to paper records. In severe cases, they can force appointment cancellations and patient diversions and potentially endanger lives. Should U.S. law require healthcare organizations to meet stricter cybersecurity standards? Let us know by writing to us at Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide — free when you join my Copyright 2025 All rights reserved.
